Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

Stelara is a brand-name drug prescribed for certain autoimmune conditions. Discover drug interactions in-depth, vaccine interactions, and more.

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies ...

Stelara was approved in 2016 to treat Crohn’s disease and in 2019 for ulcerative colitis. ... you will receive a shot every eight weeks. ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Otulfi is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous injection, a 45mg/0.5mL single-dose vial for subcutaneous injection, and a 130mg/26mL single-dose ...

GUANGZHOU, China and LONDON, May 27, 2025/ PRNewswire/-- Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma ...

The U.S. FDA has approved SELARSDI™ as interchangeable with the reference biologic Stelara ® in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is app ...

Selarsdi is FDA-approved in all Stelara-equivalent forms for psoriasis, arthritis, Crohn's, and colitis. Three biosimilar BLAs from Teva-Alvotech are under FDA review, with approvals expected in ...

Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...